Perlara

Rosebud Biosciences accelerates drug development by screening drugs against organoids (micro-organs) that have the same gene mutations as the patients. We partner with therapeutics companies to screen their drugs, and we perform our own drug discovery for rare diseases that have no existing treatments. Our organoids are also fetal-like and enable discovery of novel drug targets for pediatric diseases. This technology was validated at Stanford, published in a prestigious journal, and has already

shared extracted concept terms: companie; shared product terms: rare, disease, companie, screen; shared product theme: context and memory, health and clinical care; same category: Healthcare; shared affiliation: Y Combinator

Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies includ

shared extracted concept terms: companie; shared product terms: out, disease, gene, screen; shared product theme: context and memory; shared affiliation: Y Combinator

Craniometrix has raised over $21 million to help make dementia suck less. Dementia is tough – but it can be easier. Turns out, if you give families the right non-clinical coaching and support, you can avoid 30% of hospitalizations for these patients. And Medicare has recently started paying for that coaching. We launched our care navigation service for dementia patients in July of 2025, hit $8M of ARR, and just raised a $15M Series A. We leverage AI to provide best-in-class care, alleviating the

shared extracted concept terms: familie; shared product terms: out, familie, clinical, patient; shared product theme: health and clinical care; shared affiliation: Y Combinator

About Us Volumetric is a recognized world leader in building living multicellular tissues, with a focus on replicating discrete functions of the human body for basic mechanistic biology, laboratory testing and screening, and drug development. Founded in 2018 by Bagrat Grigoryan and Jordan Miller as a spin-out from Rice University, the full potential of our work is to build whole human organ replacements for patients, made from their own cells. Our Technology and Approach We have invented a suite

shared product terms: screen, patient, drug, out; shared product theme: context and memory, health and clinical care; same category: Healthcare; shared affiliation: Y Combinator

Founded July 2014, The Human Utility (formerly known as the Detroit Water Project) matches families needing help with utility bills to people who want to help through payments directly to utility companies. For over 40 million families in the United States, water and other essential utilities may be unaffordable. In order to afford utilities, families often forgo medication, food, and transportation. The Human Utility's platform divides a bill similar to a loan syndicate expanding the possible n

shared extracted concept terms: companie, familie; shared product terms: 2014, familie, companie, order; shared affiliation: Y Combinator

PostEra is building a modern 21st century biopharma. We're using our advances in machine learning to accelerate Medicinal Chemistry and bring more cures to patients. PostEra advances small molecule programs through partnerships with biopharma while also advancing its own internal pipeline. We've raised $26M from top investors and closed $1Bn in AI partnerships, signing multi-year agreements with Amgen, Pfizer and the NIH. PostEra also launched and led the world's largest open-science drug discov

shared product terms: launch, investor, patient, drug; shared product theme: health and clinical care; shared affiliation: Y Combinator